Welcome to LookChem.com Sign In|Join Free
  • or
4-hydroxy-6,7-dimethoxyquinoline-3-carboxylic acid is a chemical compound that belongs to the quinoline carboxylic acid class. It is a derivative of quinoline and contains a carboxylic acid functional group. 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylic acid has been studied for its potential pharmaceutical applications, including its antioxidant and anti-inflammatory properties. Its ability to chelate metal ions makes it of interest in various industrial and environmental applications. Furthermore, it has been investigated for its potential role in the treatment of various diseases, including cancer and neurodegenerative disorders, due to its ability to inhibit certain enzymes and pathways involved in disease progression.

26893-22-1

Post Buying Request

26893-22-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

26893-22-1 Usage

Uses

Used in Pharmaceutical Applications:
4-hydroxy-6,7-dimethoxyquinoline-3-carboxylic acid is used as a pharmaceutical agent for its antioxidant and anti-inflammatory properties, which can contribute to the treatment and management of various diseases and conditions.
Used in Chelating Applications:
In industrial and environmental applications, 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylic acid is used as a chelating agent to bind and remove metal ions, which can be beneficial in processes such as water treatment and metal recovery.
Used in Disease Treatment:
4-hydroxy-6,7-dimethoxyquinoline-3-carboxylic acid is used as a potential therapeutic agent in the treatment of various diseases, including cancer and neurodegenerative disorders, due to its ability to inhibit enzymes and pathways involved in disease progression.

Check Digit Verification of cas no

The CAS Registry Mumber 26893-22-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,8,9 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 26893-22:
(7*2)+(6*6)+(5*8)+(4*9)+(3*3)+(2*2)+(1*2)=141
141 % 10 = 1
So 26893-22-1 is a valid CAS Registry Number.

26893-22-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 6,7-dimethoxy-4-oxo-1H-quinoline-3-carboxylic acid

1.2 Other means of identification

Product number -
Other names 1,4-dihydro-6,7-dimethoxy-4-oxoquinoline-3-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:26893-22-1 SDS

26893-22-1Relevant academic research and scientific papers

Identification of potent and selective inhibitors of PDGF receptor autophosphorylation

Furuta, Takayuki,Sakai, Teruyuki,Senga, Terufumi,Osawa, Tatsushi,Kubo, Kazuo,Shimizu, Toshiyuki,Suzuki, Rika,Yoshino, Tetsuya,Endo, Megumi,Miwa, Atsushi

, p. 2186 - 2192 (2007/10/03)

We report the structure-activity relationship of quinoline and quinazoline derivatives, which include urea, thiourea, urethane, and acylthiourea groups, as inhibitors of the platelet-derived growth factor (PDGF) receptor autophosphorylation. Our previous studies showed that the quinoline and quinazoline derivatives including urea, thiourea, and carbamate groups were highly potent compounds as the PDGF receptor autophosphorylation inhibitor, but these compounds did not exhibit receptor selectivity between the PDGF receptor and the c-kit receptor. As a result of further synthesis and biological evaluation, we have found that the quinoline and quinazoline-acylthiourea derivatives showed not only good inhibitory activity for the PDGF receptor but also receptor selectivity between the PDGF receptor and the c-kit receptor. Furthermore N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(2- methylbenzoyl)thiourea exhibited potent oral efficacy in in vivo assay using the rat carotid balloon injury model. Therefore, the quinoline and quinazoline-acylthiourea derivatives may be expected to have potential as therapeutic agents for the treatment of restenosis.

Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase

Kubo, Kazuo,Ohyama, Shin-Ichi,Shimizu, Toshiyuki,Takami, Atsuya,Murooka, Hideko,Nishitoba, Tsuyoshi,Kato, Shinichiro,Yagi, Mikio,Kobayashi, Yoshiko,Iinuma, Noriko,Isoe, Toshiyuki,Nakamura, Kazuhide,Iijima, Hiroshi,Osawa, Tatsushi,Izawa, Toshio

, p. 5117 - 5133 (2007/10/03)

We discovered a new series of 4-phenoxyquinoline derivatives as potent and selective inhibitors of the platelet-derived growth factor receptor (PDGFr) tyrosine kinase. We researched the highly potent and selective inhibitors on the basis of both PDGFr and epidermal growth factor receptor (EGFr) inhibitory activity. First, we found a compound, Ki6783 (1), which inhibited PDGFr autophosphorylation at 0.13 μM, but it did not inhibit EGFr autophosphorylation at 100 μM. After extensive explorations, we found the two desired compounds, Ki6896 (2) and Ki6945 (3), which are substituted by benzoyl and benzamide at the 4-position of the phenoxy group on 4-phenoxyquinoline, respectively. These inhibitory activities were 0.31 and 0.050 μM, respectively, but neither of them inhibited EGFr autophosphorylation at 100 μM. We further investigated the profile of both compounds toward various tyrosine and serine/threonine kinases. The three compounds specifically inhibited PDGFr rather than the other kinases.

Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them

-

, (2008/06/13)

Heterocyclylalkylpiperidine derivatives of general formula (I) in their enantiomeric or diastereoisomeric forms or mixtures of these forms, and/or, where appropriate, in their syn or anti form or a mixture thereof, as well as any salt thereof.

A synthesis of new pyrrolo[3,2-c]quinolines

Dudouit,Houssin,Henichart

, p. 755 - 758 (2007/10/03)

A synthesis of pyrrolo[3,2-c]quinolines substituted in the 7- and 8- positions by methoxy groups and in the 3- position by an amido group is described. The structures were designed to have a crescent shape, a planar fused cyclic moiety with two ortho methoxy groups and ionisable amino or aminidinic group at pH 7.

A synthesis of 4-quinolone-3-carboxylic acids via pyrolysis of N- aryldioxopyrrolines

Mohri, Kunihiko,Kanie, Akihiko,Horiguchi, Yoshie,Isobe, Kimiaki

, p. 2377 - 2384 (2007/10/03)

A synthesis of 4-quinolone-3-carboxylic acids (8) was achieved by pyrolysis of 4,5-dimethoxycarbonyl-1-aryl-1H-pyrrole-2,3-diones (3) followed by selective demethoxycarbonylation of the resulting 2,3-dimethoxycarbonyl-4- quinolones (4) in excellent overall yields.

A novel series of 4-phenoxyquinolines: Potent and highly selective inhibitors of PDGF receptor autophosphorylation

Kubo, Kazuo,Shimizu, Toshiyuki,Ohyama, Shin-Ichi,Murooka, Hideko,Nishitoba, Tsuyoshi,Kato, Shinichiro,Kobayashi, Yoshiko,Yagi, Mikio,Isoe, Toshiyuki,Nakamura, Kazuhide,Osawa, Tatsushi,Izawa, Toshio

, p. 2935 - 2940 (2007/10/03)

A novel series of 4-phenoxyquinolines some of which showed potent and highly selective inhibitory activities for PDGF receptor autophosphorylation, was discovered. Interestingly, their structures were very similar to those of the selective inhibitors for EGF receptor autophosphorylation.

HETEROCYCLIC HYDRAZIDE DERIVATIVES OF MONOCYCLIC BETA-LACTAM ANTIBIOTICS

-

, (2008/06/13)

Antibacterial activity has been found in compounds of the formula. Compounds having the formula and pharmaceutically acceptable salts thereof, wherein: A is a bond or alkylene; Q completes a 5- or 6-membered saturated or unsaturated(including aromatic) heterocyclic ring having one or two, hetero atoms in the ring selected from nitrogen sulfur or oxygen; X is attached to an available carbon atom in the heterocyclic ring and is hydrogen or oxo; Y is attached to an available carbon atom in the heterocyclic ring and is hydrogen, amino, hydroxyl, halogen, carboxamide, nitrile, or carboxyl, except that Y is not carboxyl when the bicyclic ring completed by Q is 2-quinolyl, 3-quinolyl, or quinoxalyl; and the remaining symbols are as defined in the specification

2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines

-

, (2008/06/13)

Antibacterial activity is exhibited by 3-acylamino-2-oxoazetidines having in the 1-position an activating group of the formula STR1 wherein R is STR2 and R4 is STR3

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 26893-22-1